Application of centella asiatica triterpenoid component to preparing anti-craniocerebral injury product

Abstract

The invention relates to application of a centella asiatica triterpenoid component to preparing an anti-craniocerebral injury product, namely new application of asiaticoside and aglycone asiaic acid thereof, madecassoside and aglycone madecassoside thereof to preparation of medicaments for treating craniocerebral trauma and sequelae thereof. As proved by animal tests, the asiaticoside and the aglycone asiaic acid thereof, the madecassoside and the aglycone madecassoside thereof show obvious bioactivity and strong pharmacological action, and has the effects of treating the craniocerebral trauma and preventing and relieving cerebral trauma sequelae (such as depression and dementia). The component has stable property and rich raw material resource, is low in cost, safe and low-toxicity and provides a new medicinal source for preventing, diagnosing, detecting, protecting, treating and researching the craniocerebral trauma and preventing and relieving direct related diseases such as craniocerebral trauma sequelae and the like; and the component has a simple preparation process and high yield, is suitable for industrial production, is easy to promote and apply and has a significant value on developing and utilizing medicinal plant resources of China.

Description

technical field [0001] The present invention relates to the technical fields of medicine, food, beverage, etc., in particular to the new application of compounds in extracts of traditional Chinese medicines, and more specifically to a novel composition of Centella asiatica triterpenoids in extracts of Centella asiatica. The use, more specifically, relates to the new application of asiaticoside and its aglycone asiatic acid, madecassoside and its aglycone hydroxyasiatic acid in the preparation of anti-cranial brain injury products. Background technique [0002] (1) Overview of historical research on Centella asiatica [0003] 1 Overview [0004] Centella (Asiatic Pennywort Herb or Centella, scientific name of Chinese medicinal materials: Herba Centellae / Centella asiatica) is a commonly used traditional Chinese medicine recorded in "Chinese Pharmacopoeia", which was first recorded in "Shen Nong's Materia Medica". The dried or rooted whole grass of Centella asiatica (L.) Urb...

AI Technical Summary

Problems solved by technology

[0124] 3. Toxicology

[0305] ④Glucose solution treatment after craniocerebral injury will increase the accumulation of lactic acid in brain tissue, aggravate cerebral edema and neuron damage

[0311] ① Decompressive craniectomy will lead to embedding of bulging brain tissue at the decompression window, obstruction of venous return of embedded brain tissue, ischemic edema and necrosis of brain tissue, and formation of penetrating brain malformation over time;

[0312] ② Decompressive craniectomy without dura mater suturing will increase postoperative seizures;

[0313] ③ Decompressive craniectomy will cause cerebrospinal fluid in the ventricles to flow toward the decompression window, forming interstitial cerebral edema;

[0314] ④ Decompressive craniectomy does not suture the dura mater, so that blood seeps into the brain cistern and ventricular system from the surgical wound, which is likely to cause hydrocephalus;

[0315] ⑤ Decompressive craniectomy without suturing the dura mater will lead to instability of the brain in the cranial cavity and re-injury;

[0316] ⑥ Decompressive craniectomy without suturing the dura mater will increase the chance of intracranial infection and incision dehiscence, etc.

[0318] Clinicians have advocated the use of hyperventilation for medically refractory intracranial hypertension since the 1970s

[0357] According to literature search, so far, no new triterpenoid products of Centella asiatica have been found to be applied in the treatment of craniocerebral injury and its sequelae.

Images